Tags : Resolute Onyx DES

Medtronic Reports Results of Resolute Onyx DES in Onyx ONE

Shiwani Sharma September 27, 2019

Shots: The Onyx ONE global study involves assessing of Resolute Onyx DES vs Biosensor International’s BioFreedom DCS in ~2000 high bleeding risk patients with one month of dual antiplatelet therapy […]Read More

Medtronic Announces Onset of Onyx ONE Clear study in High

Shiwani Sharma September 11, 2018

Shots: Onyx ONE Clear study will assess one-month DAPT in high bleeding risk patients implanted with the Resolute Onyx DES in the US and Japan evaluating its safety i.e. risk […]Read More

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Eli Lilly Collaborates with Amgen to Boost the Global Supply of its COVID-19 Therapies

Takeda to Divest TachoSil to Corza Health for ~$416M

Samsung Bioepis to Present P-III Exploratory Analyses Results of Aybintio (bevacizumab, biosimilar) at ESMO 2020

Merck’s Brenzys (etanercept, biosimilar) Receives Health Canada Approval for Multiple Indications

Roche Reports Results of Actemra in P-III EMPACTA Study in Patients with COVID-19 Associated Pneumonia

Roche Launches Elecsys Anti-SARS-CoV-2 S Test for COVID-19 Antibodies

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

AstraZeneca Reports the Results of Tagrisso (osimertinib) in P-III ADAURA Study for the Adjuvant Treatment of Patients Early-Stage EGFR-Mutated Lung Cancer

Tags : Resolute Onyx DES

Medtronic Reports Results of Resolute Onyx DES in Onyx ONE

Medtronic Announces Onset of Onyx ONE Clear study in High

Latest Posts

Lilly’s Olumiant (baricitinib) Receives CHMP’s Positive Opinion for Moderate to Severe Atopic Dermatitis

Roche Presents New P-III Data of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020

Bausch Health Acquires Option to Purchase Allegro’s Ophthalmology Assets

AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Tags : Resolute Onyx DES

Latest Posts

Categories

Related Topics